Elixirgen Scientific Japan Awarded Best CDMO Finalist at Citeline Awards Japan – 2024 by Citeline
FUJISAWA (SEPTEMBER 30, 2024) – Elixirgen Scientific Japan, Inc (EsJ), a Japanese provider of synthetic mRNA contract development and manufacturing services, was awarded Best CDMO Finalist at Citeline Award Japan - 2024 by Citeline.
Recognized for its excellence in delivering innovative and high-quality solutions in mRNA manufacturing, EsJ has demonstrated significant advancements in this field since its inception of CDMO (Contract Development and Manufacturing Organization) services in September 2021. These advancements have played a pivotal role in achieving this prestigious recognition. By providing high-quality mRNA, EsJ is supporting pharmaceutical industries to accelerate R&D for mRNA medicines such as vaccines.
This esteemed recognition by Citeline is based on several key factors, including EsJ's state-of-the-art technology, commitment to quality, and impactful contributions to the pharmaceutical industry. The award highlights ESJ's efforts in enhancing the efficiency and scalability of mRNA manufacturing processes, making significant strides in the field of biotechnology.
Citeline Award Japan - 2024
Citeline Japan Awards recognize the outstanding advancements and innovations in Japanese pharma and biotech, highlighting Japan’s integral role in the global healthcare market. The awards showcase excellence in clinical trial design, technological advancements and results as well as the outstanding achievements of individuals, departments, teams or organizations. Hundreds of renowned leaders in biopharmaceuticals, CRO and diagnostics, attend the Awards to honor the greatest innovations in clinical R&D.
For more details on this recognition and insights into ESJ's contribution to the field, please visit (in Japanese only):
https://www.citeline.com/ja-jp/awards/citelinejapanawards
About Elixirgen Scientific Japan
Elixirgen Scientific Japan is a biotechnology company engaged in contract manufacturing of synthetic mRNA and stem cell-related products and services. Based on its technology for synthesizing mRNA in a cGMP-compliant environment, which is the standard for manufacturing and quality control of pharmaceutical products, and its technology for reproducibly inducing differentiation from iPS cells into various types of cells in about one week, the company aims to improve the quality of people's lives by supporting faster and lower-cost drug discovery. With a vision to revolutionize the field of regenerative medicine and drug development, EsJ continues to innovate and expand its capabilities, aspiring to be at the forefront of biotechnological and pharmaceutical advancements.
For more information, contact [email protected].
